8.595NOK-5.45%Mkt Cap: —P/E: —1d ago
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three cli…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value170.57M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.29M $
Revenue/Share—
Last Price8.595 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees8
CountryGB
SectorHealthcare
Industry—
ISINNO0010689326
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-44.48
EV/Revenue—
P/S—
P/B-97.47
EPS (TTM)-0.93
EPS (Forward)—
52W Range
8.48019% of range9.090
52W High9.090 NOK
52W Low8.480 NOK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-157.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.28M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt209.86K $
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity—
Current Ratio0.46
Quick Ratio0.46
Book Value/Sh-0.0870 NOK
Cash/Share0.0280 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.033333:1
Split DateOct 4, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.52.62M
Float168.58M
Insiders32.42%
Institutions3.74%
Technical
SMA 5024.22 (-64.5%)
SMA 20024.22 (-64.5%)
Beta-1.17
S&P 52W Chg20.80%
Avg Vol (30d)39.27K
Avg Vol (10d)3.21K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—